- Meeting abstract
- Open Access
Application of PET/CT to adjuvant chemotherapy for early lung adenocarcinoma
© Sasada et al. 2015
- Published: 16 December 2015
- Lung Cancer
- Prognostic Factor
- Tumor Size
- Adjuvant Chemotherapy
The role of adjuvant chemotherapy for stage I lung cancer is unknown. Some Japanese trials demonstrated that tegaful-uracil chemotherapy improved the prognosis of stage I lung cancer over 2 cm.
The purpose of this study is to determine the significance of the maximum standardized uptake value (SUVmax) on F-18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) images to postoperative adjuvant chemotherapy for early lung adenocarcinoma.
We reviewed 174 consecutive patients with completely resected pathological T1b-2aN0M0 lung adenocarcinoma between January 2006 and March 2011, and assessed recurrence-free interval and overall survival based on SUVmax values derived from preoperative FDG-PET/CT images. All patients were assessed by FDG-PET/CT before surgery
Ninety patients received adjuvant chemotherapy and 84 did not. Patients given adjuvant chemotherapy were older, but had the lower T status tumor than patients who were not (both, p < 0.001). Adjuvant chemotherapy conferred benefits upon recurrence-free interval and overall survival compared with observation (p = 0.007 and p = 0.004, respectively). Multivariate Cox proportional hazard analyses revealed SUVmax as an independent prognostic factor for recurrence-free interval (hazard ratio 8.03, p < 0.001). Recurrence-free interval and overall survival were significantly longer for patients who received adjuvant chemotherapy compared with those who did not in the group with SUVmax ≤ 2.6 (p < 0.001 and p < 0.001, respectively). However, recurrence-free interval and overall survival did not significantly differ between such patients in the group with SUVmax < 2.6 (p = 0.421 and p = 0.452, respectively).
Preoperative SUVmax on FDG-PET/CT images reflected the efficacy of postoperative adjuvant chemotherapy in patients with pathological T1b-2aN0M0 lung adenocarcinoma. Indications of adjuvant chemotherapy for eraly lung adenocarcinoma might be more precisely determined using SUVmax on FDG-PET/CT images together with tumor size.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.